This trial is conducted in Europe, Asia and South America. A one-year clinical trial to compare the safety of inhaled human insulin to subcutaneous insulin aspart in subjects with type 1 or type 2 diabetes and chronic obstructive pulmonary disease (COPD).
The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.
Treat-to-target dose titration scheme, pre-prandial, inhalation.
Treat-to-target dose titration scheme, pre-prandial, injection s.c.
Buenos Aires, Argentina
Buenos Aires, Argentina
Ciudad de Buenos Aires, Argentina